Altre lingue Annovis Bio, Inc.

Azioni

ANVS

US03615A1088

Mercato chiuso - Nyse Altri mercati azionari 22:00:02 02/05/2024			Dopo chiusura 00:40:27
5,45 ^USD	-10,80%		5,55	+1,83%

30/04	ANNOVIS BIO, INC. : Canaccord Genuity mantiene la raccomandazione Buy	ZM
29/04	Aggiornamento settoriale: i titoli del settore sanitario salgono nel tardo pomeriggio	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Sector Update: Health Care Stocks Edge Higher Late Afternoon	29/04
Top Midday Decliners	29/04
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading	29/04
Annovis Bio Shares Tumble After Drug Candidate Buntanetap for Alzheimer's Misses Efficacy Endpoint in Phase 2/3 Study	29/04
Annovis Bio reports positive results in mid-stage Alzheimer's treatment trial	29/04
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease	29/04
Annovis Bio, Inc. Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer?s Disease	29/04
Annovis Bio : Material Agreement - Form 8-K	26/04
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results	02/04
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans	01/04
Annovis Announces Publication That Supports Understanding of Buntanetap?s Mechanism of Action in Humans	01/04
Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Top Midday Gainers	20/03
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease	20/03
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease	20/03
Annovis Bio, Inc. Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease	20/03
Annovis Bio : Material Event - Form 8-K	20/03
Annovis Bio, Inc. announced that it expects to receive $1.025006 million in funding	15/03
An unknown buyer entered into an agreement to acquire 1.1% stake in Annovis Bio, Inc. for $1 million	15/03
North American Morning Briefing : Fed's Preferred -2-	29/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Annovis Bio, Inc.

Azioni

ANVS

US03615A1088

Altre lingue

Filtri